Glaukos inks licensing deal with Intratus for Eyelid drug delivery platform

Glaukos (NYSE:GKOS) announced today that it entered into a licensing agreement with Intratus over its Eyelid drug delivery platform.

San Clemente, Calif.-based Glaukos was granted a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive Eyelid drug delivery platform for treating presbyopia, according to a news release. Financial terms were not disclosed.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0